Clinical trials
Rituximab clinical trials
Below are recruiting rituximab clinical trials, each written for real people, not researchers. We’re tracking 281 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03394365RecruitingPhase 3
Tabelecleucel for EBV-related lymphoma after transplant treatment failure
This trial tests tabelecleucel, an immune therapy, for people whose EBV-associated post-transplant lymphoproliferative disease (PTLD) did not respond to rituximab and/or chemotherapy. It may help your immune system better control EBV-driven lymphoma after a transplant.
Duarte, CaliforniaAges Any age - NCT03523975RecruitingPhase 1/Phase 2
Testing venetoclax, lenalidomide, and rituximab for new mantle cell lymphoma
This early-phase study tests a combination of venetoclax, lenalidomide, and rituximab in people newly diagnosed with mantle cell lymphoma. It aims to control the lymphoma and see how safe and effective this approach is for newly treated patients.
Duarte, CaliforniaAges 18 years+ - NCT03844061RecruitingPhase 2
Belimumab plus rituximab for early diffuse scleroderma skin disease
This Phase 2 study tests whether combining belimumab and rituximab can improve skin thickening in people with early diffuse cutaneous systemic sclerosis (dcSSc). It may help slow the disease process and improve skin symptoms, but it also requires screening for immune and infection risks.
New York, New YorkAges 18–80 - NCT03949855RecruitingPhase 2
Belimumab plus rituximab for primary membranous nephropathy
This study tests whether adding belimumab to rituximab helps people with primary membranous nephropathy (a kidney disease) that has the right blood test marker and specific protein levels. The goal is to improve kidney outcomes and reduce disease activity while keeping treatment safe.
Birmingham, AlabamaAges 18–75 - NCT04421560RecruitingPhase 1/Phase 2
Testing pembrolizumab, ibrutinib, and rituximab for PCNSL
This Phase 1/2 study tests how well a combination of pembrolizumab, ibrutinib, and rituximab treats primary CNS lymphoma that came back or didn’t respond after prior brain treatment. It may help shrink the lymphoma and control it in the brain and fluid around the brain.
Boston, MassachusettsAges 18 years+ - NCT04518475RecruitingPhase 4
Eltrombopag with rituximab versus eltrombopag alone for ITP
This trial compares two treatment approaches for adults with primary immune thrombocytopenia (ITP), a condition where platelet counts are too low. It looks at whether adding rituximab to eltrombopag helps control ITP better and more safely.
TianjinAges 18–60 - NCT04758975RecruitingPhase 2
Venetoclax plus rituximab plus ibrutinib for early CLL
This Phase 2 trial tests a combination of three medicines to treat chronic lymphocytic leukemia (CLL) that has not been treated before and where the goal is to achieve very low remaining disease. It may help some people stay in remission longer, but eligibility depends on your age, organ function, and prior treatments.
Milan, MIAges 18–65 - NCT04989621RecruitingPhase 2
Orelabrutinib plus rituximab for relapsed follicular lymphoma
This Phase 2 study tests whether orelabrutinib combined with rituximab, followed by orelabrutinib alone for a while, can control follicular lymphoma that has come back or did not respond. It may help shrink tumors and keep the disease from worsening after initial response.
Guangzhou, GuangdongAges 18 years+ - NCT04989491RecruitingPhase 4
Single-dose rituximab to prevent EBV after kidney transplant
This trial tests whether one dose of rituximab (given around the time of transplant) can help prevent a first Epstein-Barr virus (EBV) infection and related abnormal lymph node or immune growths after kidney transplant. It is specifically for adults who are EBV-negative before receiving an EBV-positive donor kidney.
StrasbourgAges 18 years+ - NCT04998669RecruitingPhase 2
Loncastuximab plus rituximab for relapsed follicular lymphoma
This Phase 2 study tests whether loncastuximab, combined with rituximab, can shrink and control follicular lymphoma that has come back or not responded to prior treatment. It may help people who still have active disease that needs treatment and meet specific scan and blood test requirements.
Fort Myers, FloridaAges 18 years+ - NCT05018520RecruitingPhase 3
Two chemotherapy schedules for newly diagnosed low-risk DLBCL
This trial compares two different shortened treatment schedules of R-CHOP to see which one is safer and works better for people with low-risk diffuse large B-cell lymphoma (DLBCL). It aims to reduce risk from treatment while maintaining strong cancer control after an initial response.
Shanghai, Shanghai MunicipalityAges 14–75 - NCT05099471RecruitingPhase 2
Venetoclax plus rituximab for Waldenström’s macroglobulinemia
This Phase 2 study tests whether the combination of venetoclax and rituximab works better for Waldenström’s macroglobulinemia (WM) than expected from standard approaches. It is for adults with WM who have symptoms or organ/health problems caused by the disease.
BielefeldAges 18 years+ - NCT05249959RecruitingPhase 2
Loncastuximab after short treatment for relapsed mantle cell lymphoma
This Phase 2 trial studies whether adding loncastuximab after a short course of standard immunochemotherapy can better control mantle cell lymphoma that came back or didn’t respond. It specifically targets people who previously received a BTK inhibitor (or couldn’t tolerate it).
Brescia, ItalyAges 18–79 - NCT05389423RecruitingPhase 1
Pomalidomide plus chemotherapy for HIV-related lymphoma
This Phase 1 study tests whether a combination of pomalidomide and a dose-adjusted chemotherapy plan (EPOCH), with or without rituximab, can treat certain aggressive B-cell lymphomas in people living with HIV. It aims to find a safe dosing approach and see how well the treatment works for specific lymphoma types or high risk of spread to the brain.
Bethesda, MarylandAges 18 years+ - NCT05583071RecruitingPhase 2
Testing a four-drug plan for primary brain lymphoma
This Phase 2 trial studies methotrexate, tafasitamab, lenalidomide, and rituximab for primary B-cell lymphoma that starts in the brain/spinal fluid. It aims to see how well this combination works for people who cannot have certain high-dose stem cell treatment.
Stuttgart, Baden-WurttembergAges 18–99 - NCT05596786RecruitingPhase 3
Rituximab for worsening inflammatory lung scarring
This trial studies whether rituximab can slow worsening lung scarring (interstitial lung disease) when there is an inflammatory component. You would get rituximab or a placebo (inactive treatment) in a blinded, randomized design to compare safety and effectiveness.
ToursAges 18–100 - NCT05635162RecruitingPhase 2
Zanubrutinib plus rituximab for slow-growing mantle cell lymphoma
This trial studies whether combining zanubrutinib and rituximab can better control indolent (slow-growing) mantle cell lymphoma. It aims to improve how long participants can stay without the lymphoma worsening.
DerbyAges 18 years+ - NCT05645718RecruitingPhase 2
Chemo plus targeted antibodies for relapsed childhood B-ALL
This Phase 2 study tests a combination treatment for children, teens, or young adults whose B-cell acute lymphoblastic leukemia (B-ALL) has come back or did not respond to initial therapy. It may help patients who cannot safely receive certain standard medicines like anthracyclines or who cannot tolerate PEG-asparaginase.
Houston, TexasAges 1–25 - NCT05728658RecruitingPhase 1
Study of ICP-248 for relapsed or refractory B-cell cancers
This early-phase (Phase 1) study tests ICP-248 in people with certain B-cell cancers that have come back (relapsed) or did not respond to prior treatment (refractory). The goal is to learn the safest dose and whether it can help shrink or control the cancer.
Bengbu, AnhuiAges 18–80 - NCT05758831RecruitingPhase 3
Rituximab vs ocrelizumab for relapsing multiple sclerosis
This trial compares rituximab and ocrelizumab in people with relapsing-remitting multiple sclerosis (MS) to see which medicine better controls MS activity. It may help reduce future relapses and new MRI lesions.
Lyon, BronAges 18–55 - NCT05783609RecruitingPhase 2
Epcoritamab and rituximab for untreated follicular lymphoma
This phase 2 trial tests whether a combination of epcoritamab plus rituximab can work as a first treatment for follicular lymphoma. It may help people whose lymphoma is causing symptoms or affecting organs, or who have bulky disease, by targeting the lymphoma cells.
Boston, MassachusettsAges 18 years+ - NCT05786768RecruitingPhase 2/Phase 3
Obinutuzumab vs rituximab for relapsing childhood kidney syndrome
This study compares two antibody medicines, obinutuzumab and rituximab, to prevent relapses of steroid-dependent or frequently relapsing nephrotic syndrome in children. It looks at whether one option works better and is safer, including infection risk.
ParisAges 3–18 - NCT05834855RecruitingPhase 3
Rituximab versus ocrelizumab for relapsing multiple sclerosis
This Phase 3 trial compares two similar immune therapies—rituximab and ocrelizumab—to see if rituximab works about as well for relapsing multiple sclerosis. It may help you and researchers understand which option is equally effective and safe for preventing relapses and disease activity.
AmsterdamAges 18 years+ - NCT05843968RecruitingPhase 2
Rituximab or mycophenolate for steroid-dependent childhood kidney syndrome
This trial tests whether rituximab works as well as mycophenolate in children whose nephrotic syndrome (kidney condition) comes back when steroid medicines are reduced. It aims to find the safest and most effective option during a relapse.
Chongqing, Chongqing MunicipalityAges 3–16
Hear when a new Rituximab trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for rituximab?
- Yes. Clin2 currently lists 281 recruiting rituximab studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a rituximab trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a rituximab trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.